News Formal

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

  • 📰 WashTimes
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 63%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.

may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.

It’s an injectable biologic drug used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Patients usually take it twice a month. A biosimilar is a lower-cost version of a biologic that is approved by the Food and Drug Administration after regulators determine that it is highly similar to the original product. It’s not the same as a generic drug, which is a copy of a chemical-based medicine that is easier - and cheaper - to make.

The pharmacy benefit manager Optum Rx says it will add biosimilars from Boehringer Ingelheim and Sandoz, a division of the drugmaker Novartis, to its standard national formulary, or list of covered drugs, starting July 1.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 235. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
ソース: AP - 🏆 728. / 51 続きを読む »